Article
Cooperation between HIV-1 integrase natural polymorphism K156N and 3'PPT mutations in dolutegravir monotherapy failure.
The Journal of antimicrobial chemotherapy - 2 Feb 2026
van Osch Jolieke A T, Voermans Jolanda J C, Ouzerne Haajar, Cromme Alicia B H, Azugbene Ehikioya, Voskamp Mike, Krullaars Zoë, Mahmud Rizwan, Overmars Ronald J, Gorska Alicja U, Lungu Cynthia, van De Vijver David A M C, Gruters Rob A, van Kampen Jeroen J A, Mesplède Thibault
Abstract excerpt
OBJECTIVES: Mutations in the 3'-polypurine tract (3'PPT) of HIV-1 have been observed under pressure with two integrase strand transfer inhibitors, dolutegravir and cabotegravir. In the DOMONO randomized clinical trial, 3'PPT mutations emerged in a participant who experienced treatment failure under dolutegravir monotherapy. To understand the basis for this rare mutational pathway, we examined baseline viral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.